Calithera Biosciences (CALA) Receives Daily Coverage Optimism Score of 0.21
Media coverage about Calithera Biosciences (NASDAQ:CALA) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Calithera Biosciences earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.4624472910462 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- DURECT Corporation (DRRX) vs. Calithera Biosciences (CALA) Critical Survey (americanbankingnews.com)
- Calithera Biosciences Inc (CALA) Research Coverage Started at William Blair (americanbankingnews.com)
- Calithera Biosciences, Inc. – Value Analysis (NASDAQ:CALA) : October 5, 2017 (finance.yahoo.com)
- Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 4, 2017 (finance.yahoo.com)
- Andreas Halvorsen Scoops Up Abeona Therapeutics – GuruFocus.com (gurufocus.com)
Calithera Biosciences (NASDAQ CALA) traded up 8.41% during mid-day trading on Friday, hitting $17.40. 706,965 shares of the stock were exchanged. Calithera Biosciences has a 12-month low of $2.20 and a 12-month high of $20.05. The company has a 50 day moving average of $15.66 and a 200 day moving average of $14.35. The firm’s market cap is $617.28 million.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.14. The company had revenue of $7.26 million during the quarter, compared to analysts’ expectations of $4.80 million. On average, equities analysts anticipate that Calithera Biosciences will post ($0.81) earnings per share for the current fiscal year.
CALA has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and set a $19.00 target price (up previously from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. BidaskClub raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, July 7th. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a report on Tuesday, July 11th. Finally, William Blair started coverage on shares of Calithera Biosciences in a report on Thursday. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $15.50.
TRADEMARK VIOLATION WARNING: “Calithera Biosciences (CALA) Receives Daily Coverage Optimism Score of 0.21” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/06/calithera-biosciences-cala-receives-daily-coverage-optimism-score-of-0-21.html.
In other Calithera Biosciences news, VP Keith Orford sold 2,120 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $18.31, for a total value of $38,817.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The disclosure for this sale can be found here. Corporate insiders own 16.30% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.